R. Cereda

562 total citations
15 papers, 470 citations indexed

About

R. Cereda is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Surgery. According to data from OpenAlex, R. Cereda has authored 15 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Cellular and Molecular Neuroscience and 3 papers in Surgery. Recurrent topics in R. Cereda's work include Neuropeptides and Animal Physiology (5 papers), Fibroblast Growth Factor Research (4 papers) and Kruppel-like factors research (3 papers). R. Cereda is often cited by papers focused on Neuropeptides and Animal Physiology (5 papers), Fibroblast Growth Factor Research (4 papers) and Kruppel-like factors research (3 papers). R. Cereda collaborates with scholars based in Italy, France and Spain. R. Cereda's co-authors include Laura Revel, I Setnikar, Francesco Makovec, Renan Campos Chisté, Massimo Bani, Lucio C. Rovati, Angelo Delmonte, Filippo de Braud, Rastilav Bahleda and Fabrice André and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

R. Cereda

14 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Cereda Italy 10 192 148 101 92 59 15 470
Raffaello Roesel United States 13 216 1.1× 59 0.4× 148 1.5× 71 0.8× 34 0.6× 43 527
Saundra Motley United States 12 121 0.6× 40 0.3× 66 0.7× 57 0.6× 92 1.6× 18 509
Vibha Davé United States 6 238 1.2× 47 0.3× 70 0.7× 60 0.7× 50 0.8× 7 381
Yue-Xia Jia China 12 235 1.2× 212 1.4× 34 0.3× 113 1.2× 48 0.8× 12 422
H D Chern United States 9 343 1.8× 29 0.2× 176 1.7× 42 0.5× 109 1.8× 12 694
Magne Refsnes Norway 16 338 1.8× 55 0.4× 120 1.2× 155 1.7× 19 0.3× 28 624
Xuling Luo China 11 175 0.9× 80 0.5× 15 0.1× 121 1.3× 49 0.8× 15 462
Zhimin Xiao United States 10 123 0.6× 33 0.2× 220 2.2× 47 0.5× 111 1.9× 21 471
Chang Hwa Choi South Korea 13 181 0.9× 24 0.2× 29 0.3× 76 0.8× 45 0.8× 28 524
N. Eleno Spain 12 158 0.8× 42 0.3× 48 0.5× 80 0.9× 23 0.4× 21 425

Countries citing papers authored by R. Cereda

Since Specialization
Citations

This map shows the geographic impact of R. Cereda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Cereda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Cereda more than expected).

Fields of papers citing papers by R. Cereda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Cereda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Cereda. The network helps show where R. Cereda may publish in the future.

Co-authorship network of co-authors of R. Cereda

This figure shows the co-authorship network connecting the top 25 collaborators of R. Cereda. A scholar is included among the top collaborators of R. Cereda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Cereda. R. Cereda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Soria, J.C., Filippo de Braud, Rastilav Bahleda, et al.. (2014). Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Annals of Oncology. 25(11). 2244–2251. 147 indexed citations
3.
Dienstmann, Rodrigo, Bárbara Adamo, R. Cereda, et al.. (2014). Prolonged Anti-Tumor Activity of Lucitanib in Advanced Thyroid Cancer. Annals of Oncology. 25. iv354–iv354. 2 indexed citations
4.
Dienstmann, Rodrigo, Fabrice André, Jean‐Charles Soria, et al.. (2012). Significant Antitumor Activity of E-3810, a Novel FGFR and VEGFR Inhibitor, in Patients With FGFR1 Amplified Breast Cancer. Annals of Oncology. 23. ix116–ix117. 19 indexed citations
5.
Sala, F., R. Cereda, Ratislav Bahleda, et al.. (2012). 597 Pharmacokinetics of the Novel FGFR and VEGFR Inhibitor, E-3810, in Patients with Advanced Solid Tumors Participating to a Phase I/II Trial. European Journal of Cancer. 48. 183–183. 1 indexed citations
6.
Soria, J.C., Filippo de Braud, R. Cereda, et al.. (2011). First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). TPS149–TPS149. 13 indexed citations
7.
Setnikar, I, et al.. (1991). Antireactive properties of glucosamine sulfate.. PubMed. 41(2). 157–61. 74 indexed citations
8.
Setnikar, I, et al.. (1989). Pharmacological characterisation of the smooth muscle antispasmodic agent tiropramide.. PubMed. 39(9). 1114–9. 4 indexed citations
9.
Setnikar, I, et al.. (1989). Antispasmodic activity of tiropramide.. PubMed. 39(9). 1109–14. 3 indexed citations
10.
Makovec, Francesco, Massimo Bani, R. Cereda, et al.. (1987). Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.. PubMed. 37(11). 1265–8. 58 indexed citations
11.
Setnikar, I, Massimo Bani, R. Cereda, et al.. (1987). Anticholecystokinin activities of loxiglumide.. PubMed. 37(10). 1168–71. 31 indexed citations
12.
Makovec, Francesco, Massimo Bani, R. Cereda, et al.. (1987). Antispasdomic activity on the gallbladder of the mouse of CR 1409 (Lorglumide) a potent antagonist of peripheral CCK. Pharmacological Research Communications. 19(1). 41–51. 17 indexed citations
13.
Setnikar, I, Massimo Bani, R. Cereda, et al.. (1987). Loxiglumide protects against experimental pancreatitis.. PubMed. 37(10). 1172–4. 12 indexed citations
14.
Setnikar, I, Massimo Bani, R. Cereda, et al.. (1987). Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist.. PubMed. 37(6). 703–7. 58 indexed citations
15.
Makovec, Francesco, Massimo Bani, R. Cereda, et al.. (1986). Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice. Peptides. 7(6). 1159–1164. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raffaello Roesel Breakdown of academic impact, for papers by Saundra Motley Breakdown of academic impact, for papers by Vibha Davé Breakdown of academic impact, for papers by Yue-Xia Jia Breakdown of academic impact, for papers by H D Chern Breakdown of academic impact, for papers by Magne Refsnes Breakdown of academic impact, for papers by Xuling Luo Breakdown of academic impact, for papers by Zhimin Xiao Breakdown of academic impact, for papers by Chang Hwa Choi Breakdown of academic impact, for papers by N. Eleno
Rankless by CCL
2026